Analyst firms · Guggenheim · SPRB
Guggenheim SPRB price target and rating history
Spruce Biosciences Inc. (SPRB) · Health Care
Guggenheim rates Spruce Biosciences Inc. (SPRB) Buy with a $123 price target, as of its latest action on Jun 16, 2026. It has published 3 rating actions on SPRB since February 2024, including 0 upgrades and 1 downgrade. Across 6 firms with a SPRB price target in the last 12 months, the median target is $154.50. Guggenheim's $123 is 20% below that.
- Current rating
- Buy
- Price target
- $123
- Median target, all firms
- $154.50
- Actions on SPRB
- 3
Guggenheim price target on SPRB
Every Guggenheim rating on SPRB
- Jun 16, 2026
- Mar 14, 2024
- Feb 21, 2024
How other firms rate SPRB
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Lake Street | Buy | $149 | Sep 17, 2026 |
| B. Riley Securities | Buy | $160 | Jul 13, 2026 |
| Guggenheim | Buy | $123 | Jun 16, 2026 |
| Craig-Hallum | Buy | $140 | Apr 27, 2026 |
| Oppenheimer | Outperform | $283 | Dec 23, 2025 |
| Leerink Partners | Outperform | $160 | Dec 3, 2025 |
Questions about Guggenheim and SPRB
- What is Guggenheim's price target for SPRB?
- Guggenheim's latest stated price target for Spruce Biosciences Inc. (SPRB) is $123, from its action on Jun 16, 2026.
- What is Guggenheim's rating on SPRB?
- Guggenheim rates SPRB Buy, a bullish rating, as of Jun 16, 2026.
- When did Guggenheim last change its view on SPRB?
- On Jun 16, 2026, Guggenheim starts coverage at Buy, price target $123.
- How does Guggenheim's SPRB target compare with other analysts?
- Across 6 firms with a SPRB price target in the last 12 months, the median target is $154.50. Guggenheim's $123 is 20% below that.
More SPRB rating histories
All Guggenheim ratingsSPRB news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.